172 related articles for article (PubMed ID: 31429898)
1. Should I Be Tested for BRCA Mutations?
Jin J
JAMA; 2019 Aug; 322(7):702. PubMed ID: 31429898
[No Abstract] [Full Text] [Related]
2. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
3. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
4. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
[No Abstract] [Full Text] [Related]
5. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
[TBL] [Abstract][Full Text] [Related]
7. USPSTF recommends BRCA testing in women based on familial history.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E6. PubMed ID: 25618620
[No Abstract] [Full Text] [Related]
8. Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO).
Choi MC; Lim MC; Suh DH; Song YJ; Kim TJ; Chang SJ; Kim JW;
J Gynecol Oncol; 2016 Jul; 27(4):e36. PubMed ID: 27102245
[No Abstract] [Full Text] [Related]
9. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
Kauff ND; Barakat RR
Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
[No Abstract] [Full Text] [Related]
10. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma.
Piek JM; Dorsman JC; Zweemer RP; Verheijen RH; van Diest PJ; Colgan TJ
Int J Gynecol Pathol; 2003 Jul; 22(3):315-6; author reply 315-6. PubMed ID: 12819403
[No Abstract] [Full Text] [Related]
11. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
Sakamoto I; Hirotsu Y; Nakagomi H; Ouchi H; Ikegami A; Teramoto K; Amemiya K; Mochizuki H; Omata M
Cancer; 2016 Jan; 122(1):84-90. PubMed ID: 26439132
[TBL] [Abstract][Full Text] [Related]
13. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
[TBL] [Abstract][Full Text] [Related]
14. Pretest genetic counseling informs patients with BRCA mutation.
Printz C
Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
[No Abstract] [Full Text] [Related]
15. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
16. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
Rajagopal PS; Nielsen S; Olopade OI
JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
[No Abstract] [Full Text] [Related]
17. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.
Søgaard M; Kjaer SK; Gayther S
Acta Obstet Gynecol Scand; 2006; 85(1):93-105. PubMed ID: 16521688
[TBL] [Abstract][Full Text] [Related]
18. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
19. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations.
Ann Intern Med; 2005 Sep; 143(5):I47. PubMed ID: 16144889
[No Abstract] [Full Text] [Related]
20. BRCA: the breast, ovarian, and other cancer genes.
Boyd J
Gynecol Oncol; 2001 Mar; 80(3):337-40. PubMed ID: 11263927
[No Abstract] [Full Text] [Related]
[Next] [New Search]
